Page last updated: 2024-10-27

fluorouracil and Esophageal Squamous Cell Carcinoma

fluorouracil has been researched along with Esophageal Squamous Cell Carcinoma in 191 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Esophageal Squamous Cell Carcinoma: A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.

Research Excerpts

ExcerptRelevanceReference
" In this phase II prospective study, we compared the efficacy and toxicity of DP (docetaxel and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens with concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC) and analyzed the 5-year overall survival (OS) and progression free survival (PFS)."9.69Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial. ( Chen, B; Hu, Y; Jiang, H; Li, Q; Makelike, K; Xi, M; Zhu, Y, 2023)
"This phase II trial aimed to assess the safety and efficacy of paclitaxel in combination with cisplatin and 5-fluorouracil (TPF) induction chemotherapy followed by surgery for locally advanced borderline-resectable esophageal squamous cell carcinoma (BR-ESCC)."9.51Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial. ( Fong, WP; Hu, M; Hu, Y; Li, Q; Li, Y; Ren, C; Tan, Q; Wang, D; Wang, Z; Wu, J; Yang, H, 2022)
"Transient receptor potential vanilloid 2 (TRPV2) was previously shown to play an important role in the maintenance of cancer stem cells, and its specific inhibitor, tranilast, also has potential as a targeted therapeutic agent for esophageal squamous cell carcinoma (ESCC)."9.34Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC). ( Arita, T; Fujiwara, H; Ikoma, H; Konishi, H; Kosuga, T; Kubota, T; Kudou, M; Kuriu, Y; Morimura, R; Okamoto, K; Otsuji, E; Shimizu, H; Shiozaki, A; Yamamoto, Y, 2020)
"This phase II trial evaluated the efficacy of cisplatin and fluorouracil (CF)-based combination neoadjuvant chemotherapy on the outcome of patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC)."9.24Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). ( Doki, Y; Fujitani, K; Hirao, M; Kimura, Y; Kobayashi, K; Makino, T; Miyata, H; Mori, M; Motoori, M; Satoh, T; Shiraishi, O; Tamura, S; Yamasaki, M; Yano, M; Yasuda, T, 2017)
"A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squamous cell carcinoma as the second-line treatment."9.20Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. ( Han, Y; Shang, M; Shi, SB; Tian, J; Xu, J, 2015)
"We performed a phase II trial of docetaxel in combination with capecitabine to evaluate the antitumor response, toxicity, and survival in pre-treated patients with advanced esophageal squamous cell carcinoma."9.17Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma. ( Li, X; Lin, S; Lin, W; Lin, Y; Wang, H, 2013)
"To compare the efficacy and feasibility of neoadjuvant chemoradiotherapy with docetaxel plus cisplatin or with cisplatin plus fluorouracil in the treatment of local advanced esophageal squamous cell carcinoma."9.16[Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma]. ( Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S, 2012)
"This randomized clinical study was to assess and compare the efficacy and safety of two chemoradiotherapy (cisplatin + 5-fluorouracil + radiotherapy and cisplatin + docetaxel + radiotherapy) regimens in patients with unresectable local advanced oesophageal squamous cell carcinoma."9.16Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. ( Chen, H; Zhang, T; Zhao, T, 2012)
"In Japan, standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) includes preoperative chemotherapy with fluorouracil plus cisplatin followed by esophagectomy."8.12Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy. ( Demachi, K; Fujita, T; Fujiwara, H; Kojima, T; Kotani, D; Okunaka, M; Sakashita, S; Yoshino, T, 2022)
" The current study aimed to retrospectively investigate neoadjuvant radiotherapy with cisplatin and 5-fluorouracil (CF-RT) and radiotherapy with docetaxel and CF (DCF-RT) and compare their treatment outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC)."8.12Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma. ( Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Nakajo, A; Noda, M; Ohtsuka, T; Sasaki, K; Shimonosono, M; Tsuruda, Y; Uchikado, Y, 2022)
"Salvage concurrent chemoradiotherapy (60 Gy in 30 fractions) with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy was an effective and safe treatment for locoregional recurrence after curative resection of esophageal squamous cell carcinoma, especially in those approaching a complete response."8.12Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma. ( Akimoto, T; Daiko, H; Fujita, T; Fujiwara, H; Hojo, H; Ito, R; Kojima, T; Nakamura, N; Nakamura, Y; Sunakawa, H; Yano, T; Yoshino, T, 2022)
"The inclusion criteria were as follows: (1) oesophageal squamous cell carcinoma, (2) a schedule to receive three courses of induction chemotherapy (docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, 5-fluorouracil 750 mg/m2 days 1-5, every 3 weeks), (3) stage IB-III, (4) 20-75 years old, (5) 0-1 performance status, (6) preserved organ functions and (7) written informed consent."8.02A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. ( Ando, T; Fujii, H; Hamamoto, Y; Hara, H; Hosokawa, A; Ishikawa, H; Katada, C; Koizumi, W; Kojima, T; Muto, M; Nakajima, TE; Sakamoto, Y; Sugawara, M; Tahara, M; Watanabe, A, 2021)
" The present study aimed to identify cisplatin (CDDP)/5-fluorouracil (5-FU)-resistant genes in in vitro human esophageal squamous cell carcinoma with transposons."7.91THUMP domain containing 2 protein possibly induces resistance to cisplatin and 5-fluorouracil in in vitro human esophageal squamous cell carcinoma cells as revealed by transposon activation mutagenesis. ( Fukuda, K; Hayashi, M; Hayashida, T; Kawakubo, H; Kitagawa, Y; Mayanagi, S; Nakamura, R; Suda, K; Wada, N, 2019)
"5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat a variety of gastric cancers including oesophageal squamous cell carcinoma (OSCC), for which the 5-year mortality rate exceeds 85%."7.88Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB, 2018)
"This study documents the clinical efficacy and toxicity of S-1 and paclitaxel (S1/PTX) in patients with unresectable or postoperative recurrent esophageal squamous cell carcinoma (ESCC) who had been previously treated with fluorouracil (5FU), cisplatin, and docetaxel."7.88A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y, 2018)
"5-Fluorouracil (5-FU) is used for the clinical treatment of esophageal squamous cell carcinomas (ESCCs), yet it also induces chemoresistant cancer cells during treatment, which leads to the failure of the therapy."7.85A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics. ( Chen, Z; Ge, J; Jiang, H; Li, X; Ma, Q; Shi, Y; Wang, J; Wang, M; Wang, Z; Zhang, C, 2017)
" This study was aimed to compare the differences in pathologic response and survival between docetaxel/cisplatin and fluorouracil/cisplatin as neoadjuvant CRT in locally advanced esophageal squamous cell carcinoma (SCC)."7.85Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. ( Fu, JH; Li, Y; Liu, MZ; Liu, SL; Xi, M; Yang, YD; Zhang, L; Zhang, P, 2017)
"Docetaxel, cisplatin and fluorouracil (DCF) is a candidate neoadjuvant chemotherapy (NAC) regimen for esophageal squamous cell carcinoma (ESCC)."7.85The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. ( Baba, H; Baba, Y; Hiyoshi, Y; Kurashige, J; Sakamoto, Y; Watanabe, M; Yoshida, N, 2017)
"The anticancer efficacy of docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy has been reported to be better than that of conventional regimens for advanced or relapsed esophageal squamous cell carcinoma (ESCC), and may become a standard therapy for this disease."7.85Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. ( Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y, 2017)
"To retrospectively evaluate the efficacy and toxicity of definitive concurrent chemoradiotherapy (dCRT) with cisplatinum/paclitaxel versus cisplatinum/5-fluorouracil in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received nonsurgical treatment."7.83Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients. ( Guo, J; Han, X; Hu, G; Liu, L; Tang, N; Wang, Y; Wang, Z; Zhang, Q, 2016)
"To investigate the effects of nimotuzumab (h-R3) with cisplatin (DDP) or fluorouracil (5-FU) on human esophageal squamous cell carcinoma (ESCC) EC1 cells."7.81Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells. ( Huo, XQ; Ji, YH; Li, GJ; Li, WW; Lu, P; Mu, YL; Wu, JQ; Yang, XY, 2015)
"Definitive chemoradiotherapy (CRT) with 5-fluorouracil (5-FU) and cisplatin (CDDP) is one of the standard therapies for esophageal squamous cell carcinoma (ESCC); however, inter-individual variations in clinical outcomes have yet to be investigated."7.80Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Azuma, T; Hirai, M; Kuwahara, A; Miki, I; Minegaki, T; Nakamura, T; Nishiguchi, K; Okuno, T; Omatsu, H; Sakaeda, T; Tamura, T; Yamamori, M, 2014)
" In this study, 49 Japanese patients with esophageal squamous cell carcinoma (ESCC) were followed up for 5 years after treatment with a definitive 5-fluorouracil (5-FU)/cisplatin (CDDP)-based chemoradiotherapy (CRT), and the effects of genotypes of vascular endothelial growth factor (VEGF) were retrospectively revaluated in terms of prediction of long-term survival."7.78VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Kuwahara, A; Manabe, Y; Miki, I; Nakamura, T; Nishiguchi, K; Okuno, T; Sakaeda, T; Tamura, T; Yamamori, M, 2012)
"Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy."6.94Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. ( Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D, 2020)
"Paclitaxel is an active agent against oesophageal cancer and it has been proved as a potent radiation sensitiser."6.87Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2). ( Ai, D; Badakhshi, H; Cao, J; Chen, Y; Deng, J; Fan, J; Fan, M; Huang, G; Li, J; Li, L; Li, Y; Lin, Q; Liu, Q; Luo, H; Ren, W; Wei, S; Wu, K; Yang, H; Ye, J; Zhang, J; Zhao, K; Zhao, W; Zheng, X; Zhou, J; Zhu, H; Zhu, Z, 2018)
"Forty-six patients with cT4b esophageal cancer, including borderline cT4b lesions, were eligible."5.72Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil. ( Ihara, K; Kikuchi, M; Kojima, K; Kubo, T; Morita, S; Muroi, H; Nakagawa, M; Nakajima, M; Nakamura, T; Takise, S; Yamaguchi, S, 2022)
"Data from OGSG1003, a randomized phase-II trial comparing two regimens of neoadjuvant chemotherapy, cisplatin and fluorouracil plus Adriamycin and cisplatin and fluorouracil plus docetaxel, for locally advanced esophageal squamous cell carcinoma were used."5.69The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003. ( Aoyama, S; Doki, Y; Fujitani, K; Hamakawa, T; Hirao, M; Kimura, Y; Makino, T; Miyata, H; Motoori, M; Shiraishi, O; Sugimura, K; Takeno, A; Tanaka, K; Yamasaki, M; Yamashita, K; Yano, M; Yasuda, T, 2023)
" In this phase II prospective study, we compared the efficacy and toxicity of DP (docetaxel and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens with concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC) and analyzed the 5-year overall survival (OS) and progression free survival (PFS)."5.69Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial. ( Chen, B; Hu, Y; Jiang, H; Li, Q; Makelike, K; Xi, M; Zhu, Y, 2023)
"Fluorouracil (FU), platinum (PT), and taxane (TAX) therapy was the standard chemotherapy for esophageal squamous cell carcinoma (ESCC) before the era of anti-programmed death-1 antibodies."5.51A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404). ( Hirota, M; Kawada, J; Kawakami, H; Kii, T; Kurokawa, Y; Matsuyama, J; Nomura, M; Ohta, T; Sakai, D; Satoh, T; Shimokawa, T; Tsujinaka, T, 2022)
"Trifluridine/tipiracil monotherapy is feasible and shows modest activity in patients with refractory esophageal squamous cell carcinoma."5.51Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. ( Hara, H; Hironaka, S; Horimatsu, T; Ishihara, R; Kasai, H; Kato, K; Kawaguchi, A; Kikuchi, O; Kojima, T; Mori, Y; Mukai, K; Muto, M; Tada, H; Tsushima, T; Uozumi, R, 2022)
"This phase II trial aimed to assess the safety and efficacy of paclitaxel in combination with cisplatin and 5-fluorouracil (TPF) induction chemotherapy followed by surgery for locally advanced borderline-resectable esophageal squamous cell carcinoma (BR-ESCC)."5.51Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial. ( Fong, WP; Hu, M; Hu, Y; Li, Q; Li, Y; Ren, C; Tan, Q; Wang, D; Wang, Z; Wu, J; Yang, H, 2022)
"Oesophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer-associated death in the world and novel therapeutic alternatives are urgently warranted."5.43Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. ( Bai, L; Chen, DL; Chen, LZ; Ju, HQ; Lu, YX; Mo, HY; Sheng, H; Wang, DS; Wang, F; Wu, QN; Xie, D; Xu, RH; Yu, HE; Yun, JP; Zeng, ZL, 2016)
"Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2) tyrosine kinase domains."5.39Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. ( Bachman, KE; Fei, M; Greshock, J; Hou, W; Liu, L; Liu, P; Moon, H; Qin, X; Wang, H; Ye, BC; Zang, CY; Zhang, P; Zhu, X, 2013)
"In Japan, esophagectomy after two courses of 5-fluorouracil plus cisplatin is regarded a standard strategy for treating stage II or III esophageal squamous cell carcinoma (ESCC)."5.34An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus. ( Hattori, N; Hayashi, M; Iwata, N; Kanda, M; Kodera, Y; Koike, M; Nakayama, G; Omae, K; Shimizu, D; Tanaka, C; Yamada, S, 2020)
"Transient receptor potential vanilloid 2 (TRPV2) was previously shown to play an important role in the maintenance of cancer stem cells, and its specific inhibitor, tranilast, also has potential as a targeted therapeutic agent for esophageal squamous cell carcinoma (ESCC)."5.34Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC). ( Arita, T; Fujiwara, H; Ikoma, H; Konishi, H; Kosuga, T; Kubota, T; Kudou, M; Kuriu, Y; Morimura, R; Okamoto, K; Otsuji, E; Shimizu, H; Shiozaki, A; Yamamoto, Y, 2020)
"This phase II trial evaluated the efficacy of cisplatin and fluorouracil (CF)-based combination neoadjuvant chemotherapy on the outcome of patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC)."5.24Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). ( Doki, Y; Fujitani, K; Hirao, M; Kimura, Y; Kobayashi, K; Makino, T; Miyata, H; Mori, M; Motoori, M; Satoh, T; Shiraishi, O; Tamura, S; Yamasaki, M; Yano, M; Yasuda, T, 2017)
"A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squamous cell carcinoma as the second-line treatment."5.20Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. ( Han, Y; Shang, M; Shi, SB; Tian, J; Xu, J, 2015)
"We performed a phase II trial of docetaxel in combination with capecitabine to evaluate the antitumor response, toxicity, and survival in pre-treated patients with advanced esophageal squamous cell carcinoma."5.17Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma. ( Li, X; Lin, S; Lin, W; Lin, Y; Wang, H, 2013)
"To compare the efficacy and feasibility of neoadjuvant chemoradiotherapy with docetaxel plus cisplatin or with cisplatin plus fluorouracil in the treatment of local advanced esophageal squamous cell carcinoma."5.16[Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma]. ( Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S, 2012)
"This randomized clinical study was to assess and compare the efficacy and safety of two chemoradiotherapy (cisplatin + 5-fluorouracil + radiotherapy and cisplatin + docetaxel + radiotherapy) regimens in patients with unresectable local advanced oesophageal squamous cell carcinoma."5.16Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. ( Chen, H; Zhang, T; Zhao, T, 2012)
"The standard preoperative treatment for resectable locally advanced esophageal squamous cell carcinoma (LAESCC) in Japan is docetaxel, cisplatin (CDDP), and 5-fluorouracil."4.31Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin. ( Daiko, H; Hashimoto, T; Hirose, T; Honma, Y; Ikeda, G; Ishiyama, K; Itoyama, M; Kadono, T; Kato, K; Oguma, J; Ohara, A; Sekine, S; Yamamoto, S; Yokoyama, K, 2023)
"We aimed to evaluate the efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy over cisplatin and 5-fluorouracil (CF) in patients with surgically resectable advanced esophageal squamous cell carcinoma (ESCC), using real-world data from 85 esophageal centers."4.31Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan. ( Doki, Y; Kakeji, Y; Kawakubo, H; Kitagawa, Y; Matsuda, S; Muto, M; Okamura, A; Okui, J; Takemura, R; Takeuchi, H; Watanabe, M, 2023)
"This study aimed to clarify the impact of the average relative dose intensity (RDI) of neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-NAC) for resectable locally advanced esophageal squamous cell carcinoma (ESCC)."4.31Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients. ( Hiraki, Y; Imano, M; Kato, H; Momose, K; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T, 2023)
"In Japan, standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) includes preoperative chemotherapy with fluorouracil plus cisplatin followed by esophagectomy."4.12Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy. ( Demachi, K; Fujita, T; Fujiwara, H; Kojima, T; Kotani, D; Okunaka, M; Sakashita, S; Yoshino, T, 2022)
" The current study aimed to retrospectively investigate neoadjuvant radiotherapy with cisplatin and 5-fluorouracil (CF-RT) and radiotherapy with docetaxel and CF (DCF-RT) and compare their treatment outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC)."4.12Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma. ( Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Nakajo, A; Noda, M; Ohtsuka, T; Sasaki, K; Shimonosono, M; Tsuruda, Y; Uchikado, Y, 2022)
"Salvage concurrent chemoradiotherapy (60 Gy in 30 fractions) with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy was an effective and safe treatment for locoregional recurrence after curative resection of esophageal squamous cell carcinoma, especially in those approaching a complete response."4.12Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma. ( Akimoto, T; Daiko, H; Fujita, T; Fujiwara, H; Hojo, H; Ito, R; Kojima, T; Nakamura, N; Nakamura, Y; Sunakawa, H; Yano, T; Yoshino, T, 2022)
"The inclusion criteria were as follows: (1) oesophageal squamous cell carcinoma, (2) a schedule to receive three courses of induction chemotherapy (docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, 5-fluorouracil 750 mg/m2 days 1-5, every 3 weeks), (3) stage IB-III, (4) 20-75 years old, (5) 0-1 performance status, (6) preserved organ functions and (7) written informed consent."4.02A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. ( Ando, T; Fujii, H; Hamamoto, Y; Hara, H; Hosokawa, A; Ishikawa, H; Katada, C; Koizumi, W; Kojima, T; Muto, M; Nakajima, TE; Sakamoto, Y; Sugawara, M; Tahara, M; Watanabe, A, 2021)
"5-Fluorouracil (5-FU) is a chemotherapeutic agent commonly used to treat esophageal squamous cell carcinoma (ESCC), but acquisition of chemoresistance frequently occurs and the underlying mechanisms are not fully understood."3.91MicroRNA-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id-1. ( Chan, KT; Chan, KW; Cheung, ALM; Cui, D; Guan, XY; Han, L; Lam, AKY; Law, SYK; Lee, NPY; Li, B; Ma, S; Qin, YR; Tsao, SW; Xu, WW; Zhu, Y, 2019)
"Platinum plus 5-fluorouracil (FP) is a first-line regimen of palliative chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma (RM-ESCC)."3.91S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma. ( Boku, N; Hirano, H; Honma, Y; Ito, T; Iwasa, S; Kato, K; Okita, N; Shoji, H; Takashima, A, 2019)
"The aim of this study was to investigate PD-L1 expression and its association with prognosis in esophageal squamous cell carcinoma (ESCC) before and after neoadjuvant chemotherapy (5-fluorouracil and cisplatin, NAC-FP)."3.91Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8 ( Arimoto, A; Fujita, M; Fukuoka, E; Kakeji, Y; Matsuda, T; Nakamura, T; Oshikiri, T; Sawada, R; Sugita, Y; Suzuki, S; Takiguchi, G; Tanaka, T; Yamashita, K, 2019)
" The phytochemical curcumin is a potential treatment for Esophageal Squamous Cell Carcinoma (ESCC)."3.91Tetrahydrocurcumin, Curcumin, and 5-Fluorouracil Effects on Human Esophageal Carcinoma Cells. ( Geusz, ME; Jamasbi, RJ; Pendleton, EG, 2019)
"This study documents the clinical efficacy and toxicity of S-1 and paclitaxel (S1/PTX) in patients with unresectable or postoperative recurrent esophageal squamous cell carcinoma (ESCC) who had been previously treated with fluorouracil (5FU), cisplatin, and docetaxel."3.88A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y, 2018)
"5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat a variety of gastric cancers including oesophageal squamous cell carcinoma (OSCC), for which the 5-year mortality rate exceeds 85%."3.88Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB, 2018)
"Neoadjuvant chemotherapy (NAC) involving two cycles of cisplatin plus fluorouracil is recommended in Japan as a standard treatment for resectable, locally advanced esophageal squamous cell carcinoma (ESCC)."3.88Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma. ( Fujiwara, Y; Gyobu, K; Hashiba, R; Ihara, T; Kishida, S; Lee, S; Naka, R; Nishiyama, M; Osugi, H; Takemura, M, 2018)
"5-Fluorouracil (5-FU) is used for the clinical treatment of esophageal squamous cell carcinomas (ESCCs), yet it also induces chemoresistant cancer cells during treatment, which leads to the failure of the therapy."3.85A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics. ( Chen, Z; Ge, J; Jiang, H; Li, X; Ma, Q; Shi, Y; Wang, J; Wang, M; Wang, Z; Zhang, C, 2017)
" This study was aimed to compare the differences in pathologic response and survival between docetaxel/cisplatin and fluorouracil/cisplatin as neoadjuvant CRT in locally advanced esophageal squamous cell carcinoma (SCC)."3.85Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. ( Fu, JH; Li, Y; Liu, MZ; Liu, SL; Xi, M; Yang, YD; Zhang, L; Zhang, P, 2017)
"The anticancer efficacy of docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy has been reported to be better than that of conventional regimens for advanced or relapsed esophageal squamous cell carcinoma (ESCC), and may become a standard therapy for this disease."3.85Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. ( Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y, 2017)
"Docetaxel, cisplatin and fluorouracil (DCF) is a candidate neoadjuvant chemotherapy (NAC) regimen for esophageal squamous cell carcinoma (ESCC)."3.85The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. ( Baba, H; Baba, Y; Hiyoshi, Y; Kurashige, J; Sakamoto, Y; Watanabe, M; Yoshida, N, 2017)
" We found that fluorouracil (5-FU)-resistant esophageal squamous cell carcinoma cell lines, established through exposure to increasing concentrations of 5-FU, showed upregulation of Id1, IGF2, and E2F1."3.83Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance. ( Chan, KT; Chan, KW; Cheung, AL; Guan, XY; He, QY; Law, S; Lee, NP; Li, B; Li, YY; Qin, YR; Tam, PY; Tsao, SW; Xu, WW; Yuen, HF, 2016)
"To retrospectively evaluate the efficacy and toxicity of definitive concurrent chemoradiotherapy (dCRT) with cisplatinum/paclitaxel versus cisplatinum/5-fluorouracil in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received nonsurgical treatment."3.83Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients. ( Guo, J; Han, X; Hu, G; Liu, L; Tang, N; Wang, Y; Wang, Z; Zhang, Q, 2016)
"To investigate the effects of nimotuzumab (h-R3) with cisplatin (DDP) or fluorouracil (5-FU) on human esophageal squamous cell carcinoma (ESCC) EC1 cells."3.81Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells. ( Huo, XQ; Ji, YH; Li, GJ; Li, WW; Lu, P; Mu, YL; Wu, JQ; Yang, XY, 2015)
" We examined the effects of celecoxib, a COX-2 inhibitor, in enhancing the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma (ESCC) by reducing the COX-2 activity."3.80A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. ( Akanuma, N; Akutsu, Y; Hanari, N; Hoshino, I; Hu, X; Isozaki, Y; Komatsu-Akimoto, A; Matsubara, H; Mori, M; Mutallip, M; Qin, W; Yusup, G, 2014)
"Definitive chemoradiotherapy (CRT) with 5-fluorouracil (5-FU) and cisplatin (CDDP) is one of the standard therapies for esophageal squamous cell carcinoma (ESCC); however, inter-individual variations in clinical outcomes have yet to be investigated."3.80Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Azuma, T; Hirai, M; Kuwahara, A; Miki, I; Minegaki, T; Nakamura, T; Nishiguchi, K; Okuno, T; Omatsu, H; Sakaeda, T; Tamura, T; Yamamori, M, 2014)
" In this study, 49 Japanese patients with esophageal squamous cell carcinoma (ESCC) were followed up for 5 years after treatment with a definitive 5-fluorouracil (5-FU)/cisplatin (CDDP)-based chemoradiotherapy (CRT), and the effects of genotypes of vascular endothelial growth factor (VEGF) were retrospectively revaluated in terms of prediction of long-term survival."3.78VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Kuwahara, A; Manabe, Y; Miki, I; Nakamura, T; Nishiguchi, K; Okuno, T; Sakaeda, T; Tamura, T; Yamamori, M, 2012)
"Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy."2.94Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. ( Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D, 2020)
"Paclitaxel is an active agent against oesophageal cancer and it has been proved as a potent radiation sensitiser."2.87Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2). ( Ai, D; Badakhshi, H; Cao, J; Chen, Y; Deng, J; Fan, J; Fan, M; Huang, G; Li, J; Li, L; Li, Y; Lin, Q; Liu, Q; Luo, H; Ren, W; Wei, S; Wu, K; Yang, H; Ye, J; Zhang, J; Zhao, K; Zhao, W; Zheng, X; Zhou, J; Zhu, H; Zhu, Z, 2018)
"Multivariable analyses indicated only esophageal stenosis as a common factor for poor prognosis."2.84Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). ( Ando, N; Fukuda, H; Igaki, H; Ishikura, S; Katayama, H; Kato, H; Kato, K; Kawano, T; Kimura, Y; Kitagawa, Y; Kojima, T; Kosugi, S; Nakamura, K; Okabe, H; Okuno, T; Shinoda, M; Toh, Y; Tsubosa, Y; Wakabayashi, M, 2017)
"For these patients with metastatic esophageal cancer, chemotherapy is generally indicated."2.84Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus. ( Hayata, K; Iwahashi, M; Katsuda, M; Matsumura, S; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H, 2017)
"This multicenter trial included esophageal cancer patients with clinical T4 disease and/or unresectable regional lymph node metastasis."2.80Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). ( Ando, N; Fukuda, H; Ishikura, S; Kato, H; Kato, K; Kawano, T; Kimura, Y; Kosugi, S; Minashi, K; Nakamura, K; Okabe, H; Shinoda, M; Toh, Y; Tsubosa, Y, 2015)
" Adverse events, treatment response and follow-up data were collected."2.80Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer. ( Li, QL; Qiu, MQ; Wang, T; Yang, JS, 2015)
"Dose escalation in esophageal cancer based on (18)FDG-PET/CT has been safely achieved up to 70Gy using the SIB technique."2.80Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18)FDG-PET/CT for esophageal cancer. ( Cai, XW; Feng, W; Fu, XL; Liu, Q; Yao, ZF; Yu, W; Zhang, Q; Zhang, YJ; Zhu, ZF, 2015)
"The predominant histological types of esophageal cancer are adenocarcinoma and squamous cell carcinoma."2.55Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma. ( Baba, H; Baba, Y; Maehara, Y; Nakashima, Y; Oki, E; Saeki, H; Shigaki, H; Watanabe, M; Yoshida, N, 2017)
"The treatment for esophageal squamous cell carcinoma (SCC) depends on its etiology."2.49Treatment options for esophageal squamous cell carcinoma. ( Kato, H; Nakajima, M, 2013)
"The prognostic impact of postoperative anastomotic leakage (AL) and pneumonia on survival was evaluated."1.91Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers. ( Doki, Y; Kakeji, Y; Kawakubo, H; Kitagawa, Y; Matsuda, S; Muto, M; Okamura, A; Okui, J; Takemura, R; Takeuchi, H; Watanabe, M, 2023)
"Forty-six patients with cT4b esophageal cancer, including borderline cT4b lesions, were eligible."1.72Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil. ( Ihara, K; Kikuchi, M; Kojima, K; Kubo, T; Morita, S; Muroi, H; Nakagawa, M; Nakajima, M; Nakamura, T; Takise, S; Yamaguchi, S, 2022)
"However, patients with esophageal cancer and PD-L1 CPS ≥ 10 may gain the most LYs from initial PPF treatment."1.72Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis. ( Ding, D; Liu, K; Peng, L; Zhou, Y; Zhu, Y, 2022)
"She was diagnosed with esophageal cancer (cT3N2M0, stage III)."1.56A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy. ( Asano, T; Fujiki, K; Furumoto, Y; Hayakawa, Y; Horiuchi, T; Kobayashi, K; Matsumoto, T; Matsuoka, M; Misumi, Y; Miura, N; Nozaka, T; Sakamoto, N, 2020)
"Esophageal cancer is increasingly common and carries a poor prognosis."1.56Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis. ( Bateman, A; Byrne, JP; Grace, BL; Iveson, T; Jackson, A; Kelly, JJ; Noble, F; Pucher, PH; Rahman, SA; Rees, C; Underwood, TJ; Walker, RC, 2020)
"Niclosamide is an FDA‑approved anthelmintic drug, and may elicit antineoplastic effects through direct STAT3 inhibition, which has been revealed in numerous human cancer cells."1.56Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents. ( Chen, YK; Hsu, YJ; Lee, MC; Lin, BR, 2020)
"To investigate the relationship between treatment-related lymphopenia and pathologic response to neoadjuvant chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC)."1.51Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy. ( Hu, Y; Li, Q; Liu, M; Liu, S; Xi, M; Yang, H; Zhao, L; Zhou, S, 2019)
"The incidence of elderly patients with esophageal cancer (OC) is increasing as the population ages."1.51Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers. ( Hu, Y; Huang, C; Li, Q; Liu, H; Liu, M; Yuan, Y; Zhang, W; Zhu, Y, 2019)
"High (≥ 3) dysphagia scores were significantly associated with high incidences of grade 3/4 febrile neutropenia (FN) (79."1.51Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer. ( Doki, Y; Hagi, T; Kimura, Y; Makino, T; Mori, M; Motoori, M; Nishida, N; Sakai, D; Satoh, T; Tanaka, K; Yamasaki, M, 2019)
"Esophageal fistula was observed in 28 patients (24%)."1.48Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study. ( Fukutomi, A; Hamauchi, S; Kawakami, T; Kito, Y; Machida, N; Ogawa, H; Omae, K; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T; Yoshida, Y, 2018)
"DCF-R treatment for advanced cervical esophageal cancer could be completed by the careful administration; although a strong blood toxicity might occur, this treatment may provide the chance to obtain favorable prognosis with larynx preservation."1.48Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer. ( Heishi, T; Ishida, H; Ito, K; Kamei, T; Konno-Kumagai, T; Maruyama, S; Okamoto, H; Onodera, Y; Sakurai, T; Sato, C; Taniyama, Y; Teshima, J, 2018)
"Esophageal squamous cell carcinoma (ESCC) exhibits good reactivity to chemoradiation therapy (CRT)."1.48Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: A retrospective study. ( Baatar, S; Gombodorj, N; Kumakura, Y; Kuriyama, K; Kuwano, H; Miyazaki, T; Nishiyama, M; Sakai, M; Shirabe, K; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T; Yoshida, T, 2018)
"Myocardial metastasis for esophageal squamous cell carcinoma(ESCC)is relatively rare and it is diagnosed as a part of widespread metastasis in the terminal stage."1.48[A Case of Myocardial Metastasis of Esophageal Squamous Cell Carcinoma]. ( Akaishi, T; Hakamada, K; Mitsuhashi, Y; Muroya, T; Sato, K; Suzuki, T; Tsuruta, S; Umemura, K; Umetsu, S; Wajima, N; Wakasa, Y; Yachi, T; Yoshida, T, 2018)
"According to recent statistics, esophageal cancer is the eighth most common cancer in Iran."1.46EGFR Expression in Patients with Esophageal Squamous Cell Carcinoma and its Association with Pathologic Response to Preoperative Chemoradiotherapy: A Study in Northeastern Iran. ( Abdollahi, A; Aledavoud, SA; Anvari, A; Anvari, K; Forghani, MN; Ghaffarzadegan, K; Memar, B; Seilanian Toussi, M; Shahidsales, S; Sima, HR, 2017)
"50 patients with advanced esophageal cancer were treated with a continuous infusion of CF, 5-FU, and CDDP, and the short-term effects, adverse reactions, and survival periods after treatment were analyzed."1.46Continuous infusion of a large dose of CF (folinic acid) and 5-FU combined with CDDP in the treatment of advanced esophageal cancer. ( Cai, HX; Zhu, ZA; Zhu, ZQ, 2017)
"Esophageal squamous cell carcinoma (ESCC) is the second common cancer in Henan province and is well-known for aggressiveness and dismal prognosis."1.46All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma. ( Cui, H; Li, D; Li, N; Li, S; Lian, J; Lu, T; Lu, Y; Sang, L; Wang, Y; Yu, JJ; Zhang, L; Zheng, X, 2017)
"Information about 406 consecutive esophageal cancer patients with resectable disease who underwent surgery with neoadjuvant chemotherapy consisting of cisplatin plus 5-fluorouracil or who underwent definitive CRT was reviewed."1.43Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis. ( Abe, T; Andoh, M; Kadowaki, S; Kodaira, T; Komori, A; Masuishi, T; Muro, K; Muto, M; Narita, Y; Niwa, Y; Nomura, M; Oze, I; Tachibana, H; Tajika, M; Taniguchi, H; Uemura, N; Ura, T, 2016)
"Oesophageal cancer is a highly aggressive disease with about 50% of patients presenting with advanced or metastatic disease at initial diagnosis."1.43Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review. ( Bai, L; Cheng, Z; Dai, G; Han, Z; Liang, P; Liu, F; Tan, S; Yu, J; Yu, X; Zhou, F, 2016)
"Oesophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer-associated death in the world and novel therapeutic alternatives are urgently warranted."1.43Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. ( Bai, L; Chen, DL; Chen, LZ; Ju, HQ; Lu, YX; Mo, HY; Sheng, H; Wang, DS; Wang, F; Wu, QN; Xie, D; Xu, RH; Yu, HE; Yun, JP; Zeng, ZL, 2016)
"Indications for surgery for esophageal cancer often do not include cases with SCLN metastasis because the latter is considered distant metastasis."1.42Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. ( Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M, 2015)
"We aimed to identify esophageal squamous cell carcinoma (ESCC) stem-like cells, the epigenetic mechanism and identify novel biomarkers for targeting ESCC CSCs."1.42Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity. ( Chen, X; Gao, Q; Huang, L; Li, F; Li, J; Li, S; Ping, Y; Wang, D; Wang, L; Yang, L; Yue, D; Zhang, T; Zhang, Y, 2015)
"However, the esophageal cancer recurred, and subtotal esophagectomy was performed in January 2011."1.40[A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy]. ( Kigawa, G; Matsubara, T; Matsumiya, A; Mizukami, H; Nemoto, H; Saito, M; Tanaka, J; Tate, G; Umemoto, T, 2014)
"Esophageal obstruction prior to CCRT, residual tumor according to the first follow-up endoscopy, and poor follow-up computed tomography responses were significantly associated with locoregional failure."1.40Local control may be the key in improving treatment outcomes of esophageal squamous cell carcinoma undergoing concurrent chemoradiation. ( Kim, HW; Kim, JH; Kim, JW; Lee, CG; Lee, IJ; Lee, YC; Park, H; Park, JJ; Youn, YH, 2014)
"We encountered a case of esophageal squamous cell carcinoma (ESCC) with submucosal tumor (SMT)-like tumor in the cardia of the stomach, formed by direct invasion of the gastric wall."1.39[A case of esophageal squamous cell carcinoma with submucosal tumor-like tumor due to direct invasion of the gastric wall]. ( Fujiwara, H; Ichikawa, D; Ikoma, H; Komatsu, S; Konishi, H; Kubota, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Nako, Y; Okamoto, K; Otsuji, E; Sakakura, C; Shiozaki, A, 2013)
"Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2) tyrosine kinase domains."1.39Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. ( Bachman, KE; Fei, M; Greshock, J; Hou, W; Liu, L; Liu, P; Moon, H; Qin, X; Wang, H; Ye, BC; Zang, CY; Zhang, P; Zhu, X, 2013)

Research

Studies (191)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's124 (64.92)24.3611
2020's67 (35.08)2.80

Authors

AuthorsStudies
Okunaka, M1
Kotani, D1
Demachi, K1
Fujiwara, H6
Sakashita, S1
Yoshino, T3
Fujita, T4
Kojima, T12
Hsieh, JC1
Chiang, PC1
Hung, TM1
Chao, YK3
Kuo, YC1
Wen, CT1
Su, PJ1
Peng, MT1
Chen, HW1
Liu, HL1
Chang, HK2
Wu, MH1
Wang, HM1
Okadome, K2
Baba, Y6
Yasuda-Yoshihara, N1
Nomoto, D2
Yagi, T1
Toihata, T1
Ogawa, K4
Sawayama, H1
Ishimoto, T3
Iwatsuki, M2
Iwagami, S2
Miyamoto, Y2
Yoshida, N6
Watanabe, M13
Komohara, Y1
Baba, H5
Yoshida, T4
Nishino, T1
Goto, M1
Inoue, S1
Fujiwara, S1
Takizawa, H1
Tangoku, A1
Uehara, H1
Bando, Y1
Mori, Y1
Kikuchi, O1
Horimatsu, T1
Hara, H6
Hironaka, S2
Kato, K13
Tsushima, T4
Ishihara, R1
Mukai, K1
Uozumi, R1
Tada, H1
Kasai, H1
Kawaguchi, A1
Muto, M7
Ishikawa, Y1
Suzuki, M1
Yamaguchi, H1
Seto, I1
Machida, M1
Takagawa, Y1
Jingu, K1
Kikuchi, Y1
Murakami, M2
Zhu, Y4
Liu, K2
Ding, D1
Zhou, Y2
Peng, L1
Nagata, Y3
Kageyama, S1
Ishikawa, T3
Kokura, S1
Okayama, T2
Abe, T3
Otsuka, K3
Ariyoshi, T1
Taniguchi, K1
Kobayashi, S2
Shimada, H1
Yajima, S1
Suzuki, T3
Hirano, S1
Tsuchikawa, T1
Shichinohe, T1
Ueda, S1
Kanetaka, K2
Yoneda, A2
Wada, H3
Doki, Y15
Yamaue, H3
Katsuda, M3
Ohi, M1
Yasuda, H1
Kondo, K1
Kataoka, M1
Kodera, Y3
Koike, M3
Shiraishi, T1
Miyahara, Y1
Goshima, N1
Fukuda, E1
Yamaguchi, K2
Sato, E1
Ikeda, H1
Yamada, T2
Osako, M1
Hirai, K1
Miyamoto, H1
Watanabe, T1
Shiku, H1
Tang, K1
Toyozumi, T1
Murakami, K1
Sakata, H1
Kano, M1
Endo, S1
Matsumoto, Y1
Suito, H1
Takahashi, M1
Sekino, N1
Otsuka, R1
Kinoshita, K1
Hirasawa, S1
Hu, J1
Uesato, M1
Hayano, K1
Matsubara, H2
Nomura, M2
Kii, T3
Kawada, J1
Hirota, M1
Ohta, T1
Matsuyama, J1
Sakai, D2
Shimokawa, T1
Kurokawa, Y4
Kawakami, H3
Tsujinaka, T1
Satoh, T3
Nakajima, M3
Muroi, H2
Kikuchi, M2
Kubo, T2
Takise, S1
Ihara, K2
Nakagawa, M2
Morita, S2
Nakamura, T8
Yamaguchi, S2
Kojima, K2
Nishiwaki, N1
Noma, K1
Kunitomo, T1
Hashimoto, M1
Maeda, N1
Tanabe, S1
Sakurama, K1
Shirakawa, Y1
Fujiwara, T1
Matsuda, S6
Kitagawa, Y14
Takemura, R4
Okui, J4
Okamura, A5
Kawakubo, H7
Kakeji, Y5
Takeuchi, H7
Sasaki, K1
Tsuruda, Y1
Shimonosono, M1
Noda, M1
Uchikado, Y1
Arigami, T1
Matsushita, D1
Mori, S1
Nakajo, A1
Kurahara, H1
Ohtsuka, T1
Ito, R1
Nakamura, Y1
Sunakawa, H1
Hojo, H1
Nakamura, N2
Yano, T1
Daiko, H8
Akimoto, T2
Kadono, T1
Yamamoto, S3
Hirose, T1
Ikeda, G1
Ohara, A1
Itoyama, M1
Yokoyama, K1
Honma, Y6
Hashimoto, T1
Sekine, S1
Ishiyama, K2
Oguma, J3
Sugase, T1
Sugimura, K5
Kanemura, T1
Takeoka, T1
Yamamoto, M1
Shinno, N2
Omori, T2
Fujii, Y1
Mukai, Y1
Mikamori, M1
Hasegawa, S2
Haraguchi, N1
Akita, H1
Nishimura, J2
Matsuda, C1
Yasui, M2
Miyata, H8
Chan, WL1
Choi, CW1
Wong, IY1
Tsang, TH1
Lam, AT1
Tse, RP1
Chan, KK1
Wong, C1
Law, BT1
Cheung, EE1
Chan, SY1
Lam, KO1
Kwong, D1
Law, S3
Lin, CH1
Chuang, HN1
Hsiao, TH1
Kumar, VB1
Hsu, CH2
Huang, CY1
Lee, LW1
Mao, CL1
Ko, JL1
Hsu, CP2
Mitani, S2
Shiraishi, O8
Kanemura, H2
Suzuki, S5
Haratani, K2
Hayashi, H2
Yonesaka, K2
Chiba, Y2
Yasuda, T9
Nakagawa, K5
Aoyama, S2
Motoori, M7
Yamasaki, M10
Hirao, M4
Takeno, A4
Makino, T8
Tanaka, K5
Hamakawa, T2
Yamashita, K6
Kimura, Y10
Fujitani, K5
Yano, M5
Kurita, D1
Kanematsu, K1
Kubo, K1
Utsunomiya, D1
Kato, H4
Momose, K1
Hiraki, Y1
Yasuda, A1
Shinkai, M1
Imano, M1
Miyoshi, S1
Nishibuchi, I2
Murakami, Y2
Katsuta, T1
Imano, N2
Hirokawa, J1
Hamai, Y3
Emi, M3
Okada, M3
Umeki, Y1
Matsuoka, H1
Fujita, M3
Goto, A1
Serizawa, A1
Nakamura, K5
Akimoto, S1
Nakauchi, M1
Tanaka, T3
Shibasaki, S1
Inaba, K2
Uyama, I1
Suda, K2
Oiki, H1
Kawabata, R1
Izutani, Y1
Kitagawa, A1
Ushimaru, Y1
Ohhara, N1
Miyake, Y1
Maeda, S1
Nakata, K1
Nishikawa, K1
Miyamoto, A1
Inoue, N1
Gao, X1
Yang, ZH1
Cheng, YH1
Chi, CL1
Yang, TY1
Chuang, KH1
Wu, CE1
van Lanschot, JJ1
Wen, YW2
Jiang, H2
Makelike, K1
Chen, B1
Xi, M5
Li, Q4
Hu, Y4
Tsukamoto, Y1
Kurogi, S1
Fujishima, H1
Shibata, T2
Fumoto, S1
Nishiki, K1
Suzuki, K1
Etoh, T1
Shiraishi, N1
Fuchino, T1
Hirashita, Y1
Nakada, C1
Uchida, T1
Inomata, M1
Moriyama, M1
Hijiya, N1
Shimomura, A1
Hagiwara, T1
Yamada, K2
Yokoi, C1
Terayama, M1
Nohara, K1
Igari, T1
Kawamura, YI1
Ogo, T1
Ishihara, K1
Nishino, M1
Inokuch, M1
Sakurai, U1
Hagi, T1
Nishida, N1
Mori, M7
Ushigome, H1
Asukai, K1
Yanagimoto, Y1
Takahashi, Y1
Yamada, D1
Yamamoto, K3
Takahashi, H2
Ohue, M1
Chen, J3
Yin, W1
Yao, H1
Gu, W1
Wang, WT1
Guo, CQ1
Cui, GH1
Zhao, S1
Xiang, X1
Xiong, R1
Yu, C1
Deng, L1
Bie, J1
Xiao, D1
Chen, Z3
Li, X3
Feng, G2
Han, L1
Cui, D1
Li, B3
Xu, WW3
Lam, AKY1
Chan, KT3
Lee, NPY1
Law, SYK1
Guan, XY3
Qin, YR3
Chan, KW3
Ma, S2
Tsao, SW3
Cheung, ALM1
Hayashi, M2
Fukuda, K2
Mayanagi, S2
Nakamura, R2
Hayashida, T1
Wada, N3
Nagashima, K2
Hirano, H2
Shoji, H3
Iwasa, S4
Takashima, A3
Okita, N2
Boku, N3
Murakami, N1
Ito, Y3
Itami, J2
Kanamori, J2
Mine, S1
Imamura, Y3
Asari, T1
Osumi, H1
Nakayama, I1
Ichimura, T1
Ogura, M1
Ooki, A1
Takahari, D1
Chin, K3
Dai, H1
Shao, YW1
Tong, X1
Wu, X1
Pang, J1
Feng, A1
Yang, Z1
Lee, MC1
Chen, YK1
Hsu, YJ1
Lin, BR1
Randrian, V1
Adenis, A3
Desrame, J1
Barbier, E1
Di Fiore, F1
Lièvre, A1
Dahan, L1
Laurent-Puig, P1
Mineur, L1
Breysacher, G1
Roquin, G1
Louafi, S1
Lopez, A1
Louvet, C1
Borg, C1
Metges, JP1
Faroux, R1
Gaba, L1
Manfredi, S1
Tougeron, D1
Connell, C1
Smyth, EC1
Ueki, S1
Fujishima, F1
Kumagai, T1
Ishida, H2
Okamoto, H2
Takaya, K1
Sato, C2
Taniyma, Y1
Kamei, T2
Sasano, H1
Motegi, D1
Ichikawa, H1
Kano, Y1
Hanyu, T1
Usui, K1
Sakai, T2
Hirose, Y1
Miura, K1
Nagahashi, M1
Shimada, Y1
Sakata, J1
Kobayashi, T1
Kameyama, H1
Wakai, T1
Hayashi, Y3
Nakatsuka, R1
Nishizawa, Y1
Komatsu, H1
Miyazaki, S1
Tomokuni, A1
Komori, T1
Iwase, K1
Nakatani, Y1
Ushijima, T1
Chen, L1
Bi, S1
Wei, Q1
Zhao, Z3
Wang, C2
Xie, S1
Cui, Y1
Yang, D1
Wang, W1
Zhang, L5
Liu, H2
Guo, W1
Yao, M1
Zhang, K1
Li, W1
Zhang, Y7
Guan, F1
Tsubosa, Y6
Aoki, K1
Mizoguchi, Y1
Kitano, S1
Yachida, S1
Shiba, S1
Saeki, H3
Jogo, T2
Kawazoe, T1
Kamori, T1
Nakaji, Y1
Zaitsu, Y1
Fujiwara, M3
Iwata, N3
Egashira, A1
Nakanoko, T1
Morita, M2
Tanaka, Y1
Nakashima, Y3
Emi, Y1
Makiyama, A1
Oki, E3
Tokunaga, S1
Shimokawa, M1
Zhao, K3
Hu, S1
Huang, Y1
Ma, L1
Song, Y1
Li, M2
Kobayashi, K3
Maruya, Y1
Isagawa, Y1
Yoshimoto, T1
Migita, K1
Kawaguchi, Y1
Kuba, S1
Okada, S1
Kosaka, T1
Inoue, Y1
Adachi, T1
Hidaka, M1
Torashima, Y1
Ito, S1
Takatsuki, M1
Eguchi, S1
Kanda, M2
Shimizu, D1
Tanaka, C2
Hattori, N1
Yamada, S2
Omae, K2
Nakayama, G2
Wang, X3
Geng, X1
Zhu, L1
Pucher, PH1
Rahman, SA1
Walker, RC1
Grace, BL1
Bateman, A1
Iveson, T1
Jackson, A1
Rees, C1
Byrne, JP1
Kelly, JJ1
Noble, F1
Underwood, TJ1
Wen, Y1
Liao, D1
Miao, J1
Gui, Y1
Cai, H1
Chen, Y5
Wei, M1
Jia, Q1
Tian, H1
Sun, M1
Du, X1
Eguchi, H2
Katada, C3
Sugawara, M2
Fujii, H1
Nakajima, TE1
Ando, T2
Watanabe, A1
Sakamoto, Y3
Ishikawa, H1
Hosokawa, A2
Hamamoto, Y3
Tahara, M2
Koizumi, W2
Shiozaki, A3
Kudou, M1
Konishi, H4
Shimizu, H1
Arita, T2
Kosuga, T1
Yamamoto, Y2
Morimura, R2
Ikoma, H3
Kuriu, Y2
Kubota, T2
Okamoto, K3
Otsuji, E4
Dreyfuss, AD1
Barsky, AR1
Wileyto, EP1
Eads, JR1
Kucharczuk, JC1
Williams, NN1
Karasic, TB1
Metz, JM1
Ben-Josef, E1
Plastaras, JP1
Wojcieszynski, AP1
Zhu, H2
Rivin Del Campo, E1
Ye, J2
Simone, CB1
Zhu, Z2
Zhao, W2
Amini, A1
Zhou, J2
Wu, C1
Tang, H1
Fan, M2
Li, L3
Lin, Q2
Xia, Y1
Li, Y4
Li, J4
Mo, M1
Jia, H1
Lu, S1
Wang, J4
Nie, Y1
Wu, S2
Hamaji, M1
Haque, W1
Jeong, BK1
Shridhar, R1
Zhang, Z1
Zhu, J1
Zhang, X1
Wen, B1
Lu, Y2
Xu, W1
Marguet, S1
Delaine-Clisant, S1
Penel, N1
Bonastre, J1
Matsuura, N1
Saito, T1
Takahashi, T3
Nakajima, K3
Nakagawa, H1
Shim, YM2
Yun, J1
Im, YH1
Lee, G1
Kang, D1
Cho, J1
Kim, K1
Park, SI1
Na, KJ1
Kim, SB1
Zo, JI2
Nakaya, S1
Ogawa, R1
Hayakawa, S1
Fujihata, S1
Okubo, T1
Sagawa, H1
Matsuo, Y1
Takiguchi, S3
Wang, Z3
Hu, M1
Wu, J1
Fong, WP1
Ren, C1
Wang, D2
Tan, Q1
Yang, H5
Li, N1
Li, D1
Zheng, X2
Lian, J1
Li, S2
Cui, H1
Sang, L1
Wang, Y5
Yu, JJ1
Lu, T1
Zhang, C1
Ma, Q1
Shi, Y1
Wang, M1
Ge, J1
Anvari, K1
Sima, HR1
Seilanian Toussi, M1
Anvari, A1
Shahidsales, S1
Memar, B1
Aledavoud, SA1
Forghani, MN1
Abdollahi, A1
Ghaffarzadegan, K1
Liu, J1
Zhang, W3
Deng, W1
Yue, J1
Zhang, P4
Yang, YD1
Liu, SL3
Fu, JH2
Liu, MZ4
Yamashita, H2
Seto, Y1
Takenaka, R2
Okuma, K2
Kiritooshi, T1
Mori, K3
Fukuda, T1
Kaminishi, M1
Abe, O1
Nakajima, Y2
Kawada, K2
Tokairin, Y2
Hoshino, A1
Okada, T2
Kawano, T4
Akiyama, Y2
Iwaya, T2
Endo, F2
Chiba, T2
Takahara, T2
Nitta, H2
Koeda, K2
Mizuno, M2
Sasaki, A2
Okuno, T5
Wakabayashi, M1
Shinoda, M4
Katayama, H3
Igaki, H3
Okabe, H2
Kosugi, S2
Toh, Y2
Fukuda, H4
Ishikura, S3
Ando, N5
Mynhardt, C1
Damelin, LH1
Jivan, R1
Peres, J1
Prince, S1
Veale, RB1
Mavri-Damelin, D1
Bascoul-Mollevi, C1
Gourgou, S1
Galais, MP1
Raoul, JL1
Bouché, O1
Douillard, JY1
Etienne, PL1
Juzyna, B1
Bedenne, L1
Conroy, T1
Kumabe, A2
Zenda, S2
Motegi, A1
Onozawa, M1
Shigematsu, N2
Fujimoto, Y2
Sasaki, S1
Hirose, K1
Edahiro, K1
Korehisa, S1
Taniguchi, D1
Kudou, K1
Nakaji, YU1
Nakanishi, R1
Ando, K1
Oda, Y1
Maehara, Y2
Guo, L1
Cheng, X1
Ke, S1
Shi, W1
Miyazaki, Y2
Yu, FJ1
Shih, HY1
Wu, CY1
Chuang, YS1
Lee, JY1
Li, HP1
Fang, PT1
Tsai, DL1
Chou, SH1
Wu, IC1
Fukada, J1
Kota, R1
Koike, N1
Shiraishi, Y1
Seki, S1
Yoshida, K2
Muroya, T2
Wajima, N2
Yachi, T1
Akaishi, T1
Umetsu, S2
Wakasa, Y2
Sato, K1
Mitsuhashi, Y1
Umemura, K1
Tsuruta, S1
Hakamada, K2
Hsieh, HY1
Yeh, HL1
Chuang, CY1
Lin, JF1
Chang, CF1
Fujiwara, Y1
Lee, S1
Kishida, S1
Hashiba, R1
Gyobu, K1
Naka, R1
Nishiyama, M2
Ihara, T1
Takemura, M1
Osugi, H1
Kawakami, T1
Ogawa, H2
Shirasu, H1
Kito, Y1
Yoshida, Y1
Hamauchi, S2
Todaka, A1
Machida, N1
Yokota, T5
Yamazaki, K1
Fukutomi, A1
Onozawa, Y2
Yasui, H2
Doosti-Irani, A1
Holakouie-Naieni, K1
Rahimi-Foroushani, A1
Mansournia, MA1
Haddad, P1
Hihara, J2
Takeuchi, Y1
Takahashi, I1
Kimura, T2
Taniyama, Y1
Sakurai, T1
Heishi, T1
Teshima, J1
Maruyama, S1
Ito, K1
Onodera, Y1
Konno-Kumagai, T1
Gombodorj, N1
Yokobori, T2
Tanaka, N2
Kuriyama, K1
Kumakura, Y1
Sakai, M2
Sohda, M2
Baatar, S1
Miyazaki, T2
Shirabe, K1
Kuwano, H2
Chen, YH1
Lu, HI1
Lo, CM1
Wang, YM1
Chou, SY1
Hsiao, CC1
Huang, CC1
Shih, LH1
Chen, SW1
Li, SH1
Abbaszadegan, MR1
Taghehchian, N1
Aarabi, A1
Moghbeli, M1
Kawamoto, T1
Nihei, K1
Doki, N1
Najima, Y1
Kaito, S1
Karasawa, K1
Ai, D1
Liu, Q3
Zhang, J1
Deng, J1
Ren, W1
Wei, S1
Luo, H1
Cao, J1
Huang, G1
Wu, K1
Fan, J1
Badakhshi, H1
Huang, TC1
Lin, CC1
Wu, YC1
Chia-Hsien Cheng, J1
Lee, JM2
Wang, HP1
Huang, PM2
Hsu, FM1
Yeh, KH1
Cheng, AL1
Tzen, KY1
Huang, C1
Yuan, Y1
Liu, M2
Pendleton, EG1
Jamasbi, RJ1
Geusz, ME1
Iijima, H2
Isohashi, F2
Tsujii, Y1
Fujinaga, T1
Nagai, K1
Yoshii, S1
Sakatani, A1
Hiyama, S1
Shinzaki, S2
Takehara, T2
Takeuchi, M1
Irino, T1
Zhou, S1
Liu, S2
Zhao, L4
Chen, Q1
Hou, J1
Wu, Z1
Zhao, J1
Nagai, Y1
Harada, K2
Imai, K1
Karashima, R1
Koga, Y1
Yoshida, J1
Doi, T2
Ota, T1
Sakamoto, N2
Inoue, K1
Dohi, O1
Kamada, K1
Uchiyama, K1
Takagi, T1
Naito, Y1
Itoh, Y1
Ito, T1
Nikai, H1
Baba, S1
Hayakawa, Y1
Matsuoka, M1
Nozaka, T1
Misumi, Y1
Matsumoto, T1
Miura, N1
Furumoto, Y1
Asano, T1
Horiuchi, T1
Fujiki, K1
Fukuoka, E1
Sawada, R1
Sugita, Y1
Arimoto, A1
Takiguchi, G1
Matsuda, T1
Oshikiri, T1
Ura, T2
Kojima, Y1
Akutsu, Y2
Matsushita, H1
Kawakami, K1
Makiuchi, T1
Nagumo, R1
Hou, W1
Qin, X1
Zhu, X1
Fei, M1
Liu, P1
Liu, L2
Moon, H1
Greshock, J1
Bachman, KE1
Ye, BC1
Wang, H2
Zang, CY1
Ichikawa, D2
Shoda, K1
Komatsu, S2
Ochiai, T1
Inoue, J1
Inazawa, J1
Zhao, Y1
Bao, Q1
Schwarz, B1
Mysliwietz, J1
Ellwart, J1
Renner, A1
Hirner, H1
Niess, H1
Camaj, P1
Angele, M1
Gros, S1
Izbicki, J1
Jauch, KW1
Nelson, PJ1
Bruns, CJ1
Sakogawa, K1
Aoki, Y1
Misumi, K1
Shi, L1
Kono, K1
Horikoshi, Y1
Sun, J1
Ikura, T1
Tashiro, S1
Lin, W2
Lin, S1
Lin, Y1
Omatsu, H3
Kuwahara, A4
Yamamori, M4
Miki, I4
Tamura, T4
Nishiguchi, K4
Okamura, N1
Azuma, T3
Hirano, T1
Ozawa, K1
Hirai, M3
Sunpaweravong, S1
Puttawibul, P1
Ruangsin, S1
Laohawiriyakamol, S1
Sunpaweravong, P1
Sangthawan, D1
Pradutkanchana, J1
Raungkhajorn, P1
Geater, A1
Kajiura, S1
Yoshita, H1
Ueda, Y1
Ueda, A1
Mihara, H1
Fujinami, H1
Nishikawa, J1
Minemura, M1
Sugiyama, T1
Nako, Y1
Murayama, Y1
Nakanishi, M1
Sakakura, C1
Yusup, G1
Mutallip, M1
Qin, W1
Hu, X1
Komatsu-Akimoto, A1
Hoshino, I1
Hanari, N1
Akanuma, N1
Isozaki, Y1
Minegaki, T1
Sakaeda, T3
Furutani, A1
Sowa, Y1
Blazeby, JM1
Strong, S1
Donovan, JL1
Wilson, C1
Hollingworth, W1
Crosby, T1
Nicklin, J1
Falk, SJ1
Barham, CP1
Hollowood, AD1
Streets, CG1
Titcomb, D1
Krysztopik, R1
Griffin, SM1
Brookes, ST1
Ishikawa, K1
Nakamatsu, K1
Nishimura, Y1
O'Callaghan, C1
Fanning, LJ1
Barry, OP1
Nemoto, H1
Tate, G1
Umemoto, T1
Matsubara, T1
Mizukami, H1
Saito, M1
Kigawa, G1
Matsumiya, A1
Tanaka, J1
Shen, JX1
Li, QQ2
He, LR1
Ma, W1
Zhang, T3
Pan, J1
Shi, N1
Fan, Q1
Wang, L2
Lu, SH1
Lindner, K1
Borchardt, C1
Schöpp, M1
Bürgers, A1
Stock, C1
Hussey, DJ2
Haier, J2
Hummel, R2
Nishida, T1
Tsujii, M1
Tsutsui, S1
Kato, M1
Liu, Y1
Zheng, K1
Yan, H1
Chen, W1
Wang, S1
Yue, D1
Chen, X1
Ping, Y1
Gao, Q1
Li, F1
Yang, L1
Huang, L1
Sie, C1
Watson, DI1
Wang, T2
Ansar, A1
Michael, MZ1
Van der Hoek, M1
Omori, M1
Kobayashi, R1
Ohtomo, K1
Ordu, AD1
Nieder, C1
Geinitz, H1
Scherer, V1
Kup, PG1
Schuster, T1
Combs, SE1
Fakhrian, K1
Kim, HW1
Kim, JH1
Lee, IJ1
Kim, JW1
Lee, YC1
Lee, CG1
Park, JJ1
Youn, YH1
Park, H1
Yu, W1
Cai, XW1
Zhu, ZF1
Feng, W1
Zhang, Q2
Zhang, YJ1
Yao, ZF1
Fu, XL1
Zhang, WW1
Zhu, YJ1
Wang, QX1
Wang, XH1
Xiao, WW1
Hu, YH1
Minashi, K1
Yamashita, M1
Takenaka, HY1
Ji, YH1
Yang, XY1
Wu, JQ1
Huo, XQ1
Li, WW1
Li, GJ1
Mu, YL1
Lu, P1
Yang, JS1
Qiu, MQ1
Li, QL1
Mizusawa, J2
Tamura, S2
Taniguchi, H2
Katsura, Y1
Ohmura, Y1
Kagawa, Y1
Sakisaka, H1
Takeda, Y1
Kato, T2
Chiu, CH1
Chen, WH1
Yeh, CJ1
Tseng, CK1
Liu, YH1
Luo, LL1
Tian, J1
Shang, M1
Shi, SB1
Han, Y1
Xu, J1
Niwa, Y2
Oya, H1
Nishio, N1
Hiramatsu, M1
Kobayashi, D1
Fujii, T1
Sugimoto, H1
Nomoto, S1
Najafzadeh, N1
Mazani, M1
Abbasi, A1
Farassati, F1
Amani, M1
Okada, N1
Fujii, S2
Hayashi, R1
Lee, NP2
Tam, PY1
Li, YY1
Yuen, HF1
He, QY1
Cheung, AL2
Izumi, D1
Shiraishi, S1
Kosumi, K1
Tokunaga, R1
Taki, K1
Higashi, T1
Miyata, T1
Ida, S1
Yamashita, Y1
Ojima, T2
Nakamori, M2
Nakamura, M2
Hayata, K2
Matsumura, S1
Iwahashi, M2
Akasaka, H1
Ichinohe, D1
Kitadani, J1
Tabata, H1
Takeuchi, A1
Katada, N2
Moriya, H2
Hosoda, K2
Mieno, H2
Hoshi, K1
Honjo, H1
Hara, K1
Ozawa, D1
Koca, D1
Ozdemir, O1
Demir, D1
Akdeniz, H1
Kurt, M1
Sato, H1
Takebayashi, K1
Kawamorita, K1
Niihara, M1
Oze, I1
Kodaira, T1
Komori, A1
Narita, Y1
Masuishi, T1
Kadowaki, S1
Andoh, M1
Tachibana, H1
Uemura, N1
Tajika, M1
Muro, K1
Miyawaki, Y1
Tryakin, A1
Pokataev, I1
Kononets, P1
Fedyanin, M1
Bokhyan, V1
Malikhova, O1
Minin, K1
Shogenov, M1
Stilidi, I1
Vybarava, A1
Davydov, M1
Tjulandin, S1
Zhou, F1
Yu, X1
Liang, P1
Cheng, Z1
Han, Z1
Yu, J1
Liu, F1
Tan, S1
Dai, G1
Bai, L2
Hatogai, K1
Kadota, T1
Takiguchi, Y1
Ohtsu, A2
Satake, H1
Mochizuki, S1
Kiyota, N1
Bando, H1
Yamazaki, T1
Hu, G1
Tang, N1
Guo, J1
Han, X1
Hiyoshi, Y1
Kurashige, J1
Gemici, C1
Yaprak, G1
Batirel, HF1
Ilhan, M1
Mayadagli, A1
Li, CY1
Chu, PY1
Chen, PM1
Lin, MW1
Kuo, SW1
Lu, YX1
Chen, DL1
Wang, DS1
Chen, LZ1
Mo, HY1
Sheng, H1
Wu, QN1
Yu, HE1
Xie, D1
Yun, JP1
Zeng, ZL1
Wang, F1
Ju, HQ1
Xu, RH1
Lim, SH1
Park, SH1
Kim, HK1
Choi, YS1
Ahn, MJ1
Park, K1
Sun, JM1
Shigaki, H1
Komori, S1
Kawai, T1
Kochi, M1
Fujii, M1
Song, K1
Hagiwara, K1
Tamegai, H1
Matsuno, Y1
Takayama, Y1
Suda, H1
Takayama, T1
Zhu, ZQ1
Zhu, ZA1
Cai, HX1
Zhao, T1
Chen, H1
Mizuno, S1
Manabe, Y1
Chen, MY1
Luo, JC1
Wei, L1

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Ad[NCT03189719]Phase 3749 participants (Actual)Interventional2017-07-25Completed
Nal-IRI/LV5-FU VERSUS PACLITAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA A Multi-centre, Randomized, Non-comparative Phase II Study[NCT03719924]Phase 2106 participants (Actual)Interventional2019-03-07Active, not recruiting
A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma[NCT05213312]Phase 2/Phase 390 participants (Anticipated)Interventional2022-06-01Recruiting
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma FRONTiER Trial[NCT03914443]Phase 136 participants (Anticipated)Interventional2019-05-07Active, not recruiting
Prospective, Randomized, Multicenter, Phase II Noninferiority Study of S-1 Concurrent Intensity-modulated Radiation Therapy (IMRT) Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma[NCT02913066]Phase 288 participants (Anticipated)Interventional2016-09-30Recruiting
Paclitaxel In Combination With Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial[NCT02976909]Phase 246 participants (Actual)Interventional2016-10-31Completed
A Prospective, Phase II Study of Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy in Patients With Esophageal Squamous Cell Carcinoma[NCT04380480]Phase 263 participants (Actual)Interventional2020-02-01Completed
A Comparison of Paclitaxel in Combination With Cisplatin(TP), Carboplatin(TC) or Fluorouracil(TF) Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Squamous Cell Carcinoma: A Three-Arm Randomized Phase III Trial[NCT02459457]Phase 3321 participants (Actual)Interventional2015-07-01Completed
Dose Escalation Using a Simultaneous Integrated Boost Technique Based on 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer: a Phase I/II Trial[NCT01843049]Phase 1/Phase 240 participants (Anticipated)Interventional2013-01-31Recruiting
Measurement of the Distance Between the Corresponding Anatomical Landmarks in the Thoracic Cavity and the Incisors[NCT03720405]520 participants (Anticipated)Observational [Patient Registry]2018-07-31Recruiting
Sichuan Cancer Hospital & Institute[NCT05604950]2 participants (Actual)Observational [Patient Registry]2009-01-01Completed
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903)[NCT04138212]Phase 3456 participants (Anticipated)Interventional2019-10-22Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline To Week 18 in the EORTC QLQ-C30 GHS/QoL Combined Score in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10)

"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants who were PD-L1 CPS ≥10." (NCT03189719)
Timeframe: Baseline, Week 18

InterventionScore on a Scale (Least Squares Mean)
Pembrolizumab + SOC-1.73
Placebo + SOC0.04

Change From Baseline To Week 18 in the EORTC QLQ-C30 GHS/QoL Combined Score in Participants With ESCC

"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants who had ESCC." (NCT03189719)
Timeframe: Baseline, Week 18

InterventionScore on a Scale (Least Squares Mean)
Pembrolizumab + SOC-2.00
Placebo + SOC-1.94

Change From Baseline To Week 18 in the EORTC QLQ-C30 GHS/QoL Combined Score in Participants With ESCC Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10)

"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants who had ESCC and who were PD-L1 CPS ≥10." (NCT03189719)
Timeframe: Baseline, Week 18

InterventionScore on a Scale (Least Squares Mean)
Pembrolizumab + SOC-2.36
Placebo + SOC-0.40

Change From Baseline To Week 18 in the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Combined Score in All Participants

"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants." (NCT03189719)
Timeframe: Baseline, Week 18

InterventionScore on a Scale (Least Squares Mean)
Pembrolizumab + SOC-1.74
Placebo + SOC-1.64

DOR Per RECIST 1.1 As Assessed By Investigator in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10)

For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR, and were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionMonths (Median)
Pembrolizumab + SOC10.4
Placebo + SOC5.6

DOR Per RECIST 1.1 As Assessed By Investigator in Participants With ESCC

For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR, and who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionMonths (Median)
Pembrolizumab + SOC9.1
Placebo + SOC6.1

DOR Per RECIST 1.1 As Assessed By Investigator in Participants With ESCC Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10)

For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR, and who had ESCC and were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionMonths (Median)
Pembrolizumab + SOC10.4
Placebo + SOC4.4

Duration of Response (DOR) Per RECIST 1.1 As Assessed By Investigator in All Participants

For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionMonths (Median)
Pembrolizumab + SOC8.3
Placebo + SOC6.0

Number of Participants Discontinuing Study Treatment Due to an AE

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued any study drug due to an AE was reported for each treatment arm. (NCT03189719)
Timeframe: Up to approximately 27 months

InterventionParticipants (Count of Participants)
Pembrolizumab + SOC90
Placebo + SOC74

Number of Participants With an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm. (NCT03189719)
Timeframe: Up to approximately 28 months

InterventionParticipants (Count of Participants)
Pembrolizumab + SOC370
Placebo + SOC368

Objective Response Rate (ORR) Per RECIST 1.1 As Assessed By Investigator in All Participants

ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized). (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionPercentage of Participants (Number)
Pembrolizumab + SOC45.0
Placebo + SOC29.3

ORR Per RECIST 1.1 As Assessed By Investigator in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10)

ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionPercentage of Participants (Number)
Pembrolizumab + SOC51.1
Placebo + SOC26.9

ORR Per RECIST 1.1 As Assessed By Investigator in Participants With ESCC

ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized) who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionPercentage of Participants (Number)
Pembrolizumab + SOC43.8
Placebo + SOC31.0

ORR Per RECIST 1.1 As Assessed By Investigator in Participants With ESCC Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10)

ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized) who had ESCC and who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionPercentage of Participants (Number)
Pembrolizumab + SOC51.0
Placebo + SOC28.0

OS in All Participants

Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the ITT population (all randomized). (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionMonths (Median)
Pembrolizumab + SOC12.4
Placebo + SOC9.8

OS in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10)

Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionMonths (Median)
Pembrolizumab + SOC13.5
Placebo + SOC9.4

OS in Participants With ESCC

Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the ITT population (all randomized) who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionMonths (Median)
Pembrolizumab + SOC12.6
Placebo + SOC9.8

Overall Survival (OS) in Participants With Esophageal Squamous Cell Carcinoma (ESCC) Whose Tumors Are Programmed Cell Death-Ligand 1 (PD-L1) Biomarker-Positive (Combined Positive Score [CPS] ≥10)

Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the Intent-To-Treat (ITT) population (all randomized) who had ESCC and who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionMonths (Median)
Pembrolizumab + SOC13.9
Placebo + SOC8.8

PFS Per RECIST 1.1 As Assessed By Investigator in All Participants

PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, PFS is reported here for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionMonths (Median)
Pembrolizumab + SOC6.3
Placebo + SOC5.8

PFS Per RECIST 1.1 As Assessed By Investigator in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10)

PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, PFS is reported here for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionMonths (Median)
Pembrolizumab + SOC7.5
Placebo + SOC5.5

Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) As Assessed By Investigator in Participants With ESCC

PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, PFS is reported here for all participants of the ITT population (all randomized) who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)

InterventionMonths (Median)
Pembrolizumab + SOC6.3
Placebo + SOC5.8

Change From Baseline in the EORTC QLQ-OES18 Subscale Scores in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10)

"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores representing a higher (worse) level of symptoms. Change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for participants who were PD-L1 CPS≥10 in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18

,
InterventionScore on a Scale (Least Squares Mean)
Dysphagia subscalePain subscaleReflux subscale
Pembrolizumab + SOC-7.18-3.51-0.52
Placebo + SOC1.020.074.25

Change From Baseline in the EORTC QLQ-OES18 Subscale Scores in Participants With ESCC

"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores representing a higher (worse) level of symptoms. Change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for participants with ESCC in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18

,
InterventionScore on a Scale (Least Squares Mean)
Dysphagia subscalePain subscaleReflux subscale
Pembrolizumab + SOC-1.18-4.03-0.40
Placebo + SOC3.32-2.331.09

Change From Baseline in the EORTC QLQ-OES18 Subscale Scores in Participants With ESCC Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10)

"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores representing a higher (worse) level of symptoms. Change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for participants with ESCC who were PD-L1 CPS≥10 in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18

,
InterventionScore on a Scale (Least Squares Mean)
Dysphagia subscalePain subscaleReflux subscale
Pembrolizumab + SOC-5.11-2.55-0.16
Placebo + SOC3.57-0.424.94

Change From Baseline in the EORTC Quality Of Life Questionnaire Oesophageal Module (QLQ-OES18) Subscale Scores in All Participants

"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores represent a higher (worse) level of symptoms. Per protocol, change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for all participants in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18

,
InterventionScore on a Scale (Least Squares Mean)
Dysphagia subscalePain subscaleReflux subscale
Pembrolizumab + SOC-3.18-4.78-0.22
Placebo + SOC2.36-1.850.71

Reviews

6 reviews available for fluorouracil and Esophageal Squamous Cell Carcinoma

ArticleYear
Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma.
    Annals of surgical oncology, 2023, Volume: 30, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal

2023
Chemoradiotherapy for Solitary Skeletal Muscle Metastasis from Oesophageal Cancer: Case Report and Brief Literature Review.
    Anticancer research, 2017, Volume: 37, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous

2017
A network meta-analysis of the treatments for esophageal squamous cell carcinoma in terms of survival.
    Critical reviews in oncology/hematology, 2018, Volume: 127

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Carcinoma, Squamous Cell

2018
Treatment options for esophageal squamous cell carcinoma.
    Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat

2013
Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan.
    Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 2016, Oct-20, Volume: 22, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan

2016
Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, Feb-01, Volume: 30, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci

2017

Trials

39 trials available for fluorouracil and Esophageal Squamous Cell Carcinoma

ArticleYear
Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study.
    Esophagus : official journal of the Japan Esophageal Society, 2022, Volume: 19, Issue:3

    Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Japan; Neoplasm Recu

2022
Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.
    Cancer immunology, immunotherapy : CII, 2022, Volume: 71, Issue:11

    Topics: Antibodies, Neoplasm; Antigens, Neoplasm; Cancer Vaccines; Cisplatin; Esophageal Neoplasms; Esophage

2022
A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404).
    Esophagus : official journal of the Japan Esophageal Society, 2022, Volume: 19, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophageal Squamous Cell

2022
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop

2023
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop

2023
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop

2023
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop

2023
Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial.
    Radiation oncology (London, England), 2023, Sep-12, Volume: 18, Issue:1

    Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; F

2023
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2020, Volume: 52, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progress

2020
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
    Future oncology (London, England), 2020, Volume: 16, Issue:19

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as

2020
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
    Future oncology (London, England), 2020, Volume: 16, Issue:19

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as

2020
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
    Future oncology (London, England), 2020, Volume: 16, Issue:19

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as

2020
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
    Future oncology (London, England), 2020, Volume: 16, Issue:19

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as

2020
An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
    The oncologist, 2020, Volume: 25, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Comb

2020
Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial.
    The oncologist, 2020, Volume: 25, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms;

2020
Multicenter Randomized Phase 2 Trial Comparing Chemoradiotherapy and Docetaxel Plus 5-Fluorouracil and Cisplatin Chemotherapy as Initial Induction Therapy for Subsequent Conversion Surgery in Patients With Clinical T4b Esophageal Cancer: Short-term Result
    Annals of surgery, 2021, 12-01, Volume: 274, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel

2021
Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC).
    Medicine, 2020, Dec-11, Volume: 99, Issue:50

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dose

2020
Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.
    International journal of radiation oncology, biology, physics, 2021, 08-01, Volume: 110, Issue:5

    Topics: Aged; Chemoradiotherapy; China; Cisplatin; Confidence Intervals; Dose Fractionation, Radiation; Drug

2021
Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2021, Volume: 24, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analys

2021
The efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2022, Jan-07, Volume: 35, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Dis

2022
Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial.
    Esophagus : official journal of the Japan Esophageal Society, 2022, Volume: 19, Issue:1

    Topics: Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Induction

2022
Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303).
    International journal of clinical oncology, 2017, Volume: 22, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Squamous

2017
Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 84

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma,

2017
Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
    BMJ open, 2018, 10-21, Volume: 8, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; China; Cisplatin; Cl

2018
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2019, Volume: 118, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous

2019
A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.
    Annals of surgical oncology, 2020, Volume: 27, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esoph

2020
Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell;

2013
Randomized study of antiinflammatory and immune-modulatory effects of enteral immunonutrition during concurrent chemoradiotherapy for esophageal cancer.
    Nutrition and cancer, 2014, Volume: 66, Issue:1

    Topics: Adult; Aged; Arginine; C-Reactive Protein; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; E

2014
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    American journal of clinical oncology, 2016, Volume: 39, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp

2016
Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer.
    British journal of cancer, 2014, Jul-15, Volume: 111, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradioth

2014
Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans: a phase II study.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014, Volume: 113, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C

2014
Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18)FDG-PET/CT for esophageal cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2015, Volume: 114, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do

2015
Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).
    Cancer science, 2015, Volume: 106, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam

2015
Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer.
    Internal medicine journal, 2015, Volume: 45, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2015
Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907).
    Oncology, 2015, Volume: 89, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2015
Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; C

2015
Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, 02-01, Volume: 30, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C

2017
Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
    Anticancer research, 2016, Volume: 36, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C

2016
Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
    General thoracic and cardiovascular surgery, 2016, Volume: 64, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci

2016
Preoperative chemotherapy in patients with resectable esophageal carcinoma: a single center Phase II study.
    Japanese journal of clinical oncology, 2016, Volume: 46, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co

2016
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2016
Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jan-01, Volume: 28, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2017
A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma.
    Cancer research and treatment, 2017, Volume: 49, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2017
Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co

2012
[Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2012

Other Studies

146 other studies available for fluorouracil and Esophageal Squamous Cell Carcinoma

ArticleYear
Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
    Esophagus : official journal of the Japan Esophageal Society, 2022, Volume: 19, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous

2022
Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence.
    Cancer medicine, 2021, Volume: 10, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Carboplatin; Chemoradiotherapy; Cisplatin; Esophageal Squamous Cell

2021
PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma.
    Cancer science, 2022, Volume: 113, Issue:2

    Topics: B7-H1 Antigen; Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Esophageal Neoplasms; Esophageal Squa

2022
ypN0 in Patients With Definitive cN-positive Status After Preoperative Treatment Is a Prognostic Factor in Esophageal Cancer.
    Anticancer research, 2022, Volume: 42, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant

2022
Long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma: a case report.
    Journal of medical case reports, 2022, Feb-14, Volume: 16, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous

2022
Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis.
    Advances in therapy, 2022, Volume: 39, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Ci

2022
HIF-1α stimulates the progression of oesophageal squamous cell carcinoma by activating the Wnt/β-catenin signalling pathway.
    British journal of cancer, 2022, Volume: 127, Issue:3

    Topics: beta Catenin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Esophageal Neoplasms;

2022
Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil.
    Anticancer research, 2022, Volume: 42, Issue:7

    Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans

2022
Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.
    Esophagus : official journal of the Japan Esophageal Society, 2022, Volume: 19, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage

2022
Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan.
    Annals of surgery, 2023, Jul-01, Volume: 278, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Es

2023
Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma.
    Anticancer research, 2022, Volume: 42, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage

2022
Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma.
    Esophagus : official journal of the Japan Esophageal Society, 2022, Volume: 19, Issue:4

    Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinom

2022
Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neopl

2023
Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer.
    Oncology, 2022, Volume: 100, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat

2022
AGR2 expression as a predictive biomarker for therapy response in esophageal squamous cell carcinoma.
    PloS one, 2022, Volume: 17, Issue:11

    Topics: Biomarkers; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagecto

2022
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2

    Topics: B7-H1 Antigen; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluor

2023
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2

    Topics: B7-H1 Antigen; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluor

2023
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2

    Topics: B7-H1 Antigen; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluor

2023
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2

    Topics: B7-H1 Antigen; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluor

2023
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
    Annals of surgical oncology, 2023, Volume: 30, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage

2023
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
    Annals of surgical oncology, 2023, Volume: 30, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage

2023
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
    Annals of surgical oncology, 2023, Volume: 30, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage

2023
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
    Annals of surgical oncology, 2023, Volume: 30, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage

2023
Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2

    Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluor

2023
Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients.
    Oncology, 2023, Volume: 101, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esop

2023
Long-term results of chemoradiotherapy with elective nodal irradiation for resectable locally advanced esophageal cancer in three-dimensional planning system.
    International journal of clinical oncology, 2023, Volume: 28, Issue:3

    Topics: Aged; Aged, 80 and over; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma

2023
Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:3

    Topics: Aged; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; East A

2023
Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study.
    Internal medicine (Tokyo, Japan), 2023, Volume: 62, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage

2023
[A Case Report of Stage Ⅳb Thoracic Esophageal Cancer Responding to Multidisciplinary Treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Sq

2022
Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil.
    General thoracic and cardiovascular surgery, 2023, Volume: 71, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage

2023
Treatment burden and cost-effectiveness analysis of the neoadjuvant CROSS regimen in esophageal squamous cell carcinoma: a multicenter retrospective study.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2023, Oct-27, Volume: 36, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Cost-Effectiveness Ana

2023
Association of immune-related expression profile with sensitivity to chemotherapy in esophageal squamous cell carcinoma.
    Cancer science, 2023, Volume: 114, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop

2023
Induction of Kallikrein-Related Peptidase 13 and TET2/3 by Anticancer Drugs and Poor Prognosis of Patients with Esophageal Squamous Cell Carcinoma After Preoperative Treatment.
    Annals of surgical oncology, 2024, Volume: 31, Issue:1

    Topics: Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dioxygenases; DNA-Binding Proteins; Esophageal

2024
[A Case of Esophageal Cancer with Multiple Lung Metastases Resected after Stent Placement and Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2023, Volume: 50, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea

2023
Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer.
    Annals of surgical oncology, 2019, Volume: 26, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti

2019
Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
    Oncology, 2019, Volume: 97, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxe

2019
Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
    Radiation oncology (London, England), 2019, Sep-18, Volume: 14, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophagea

2019
Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
    World journal of gastroenterology, 2019, Oct-07, Volume: 25, Issue:37

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies

2019
Tex10 promotes stemness and EMT phenotypes in esophageal squamous cell carcinoma via the Wnt/β‑catenin pathway.
    Oncology reports, 2019, Volume: 42, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Pro

2019
MicroRNA-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id-1.
    Cancer science, 2019, Volume: 110, Issue:12

    Topics: Adult; Aged; Animals; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Esophageal Neoplas

2019
THUMP domain containing 2 protein possibly induces resistance to cisplatin and 5-fluorouracil in in vitro human esophageal squamous cell carcinoma cells as revealed by transposon activation mutagenesis.
    The journal of gene medicine, 2019, Volume: 21, Issue:12

    Topics: Alleles; Cell Line, Tumor; Cisplatin; DNA Transposable Elements; Dose-Response Relationship, Drug; D

2019
Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy.
    Cancer medicine, 2020, Volume: 9, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neu

2020
Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma.
    Annals of surgical oncology, 2020, Volume: 27, Issue:5

    Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophage

2020
YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
    Cancer medicine, 2020, Volume: 9, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B

2020
Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents.
    Oncology reports, 2020, Volume: 43, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin;

2020
Anti-EGFR plus chemotherapy in unselected advanced oesophageal squamous cell carcinoma: less POWERful than expected.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:2

    Topics: Cisplatin; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; H

2020
GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy.
    BMC cancer, 2020, Feb-27, Volume: 20, Issue:1

    Topics: Antineoplastic Agents; Cell Cycle Proteins; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cel

2020
[A Case of Esophageal Cancer Achieving a Pathological Complete Response after Preoperative Docetaxel, Cisplatin, and 5-Fluorouracil Therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Es

2019
[A Case of Lymph Node Recurrence with Invasion to the Trachea after the Resection of Esophageal Cancer Treated by Multidisciplinary Treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Sq

2019
Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer.
    International journal of clinical oncology, 2020, Volume: 25, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C

2020
Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:9

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Down-Regulation;

2020
Nicotinamide N-methyltransferase decreases 5-fluorouracil sensitivity in human esophageal squamous cell carcinoma through metabolic reprogramming and promoting the Warburg effect.
    Molecular carcinogenesis, 2020, Volume: 59, Issue:8

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cellular

2020
RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma: A Large-cohort Observational Study (KSCC1307).
    Annals of surgery, 2022, 04-01, Volume: 275, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Chemoradiother

2022
A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR.
    BMC cancer, 2020, Jun-10, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols

2020
Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
    Journal of gastrointestinal cancer, 2021, Volume: 52, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; D

2021
Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy.
    Cancer medicine, 2020, Volume: 9, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C

2020
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020, Volume: 46, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap

2020
A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma.
    Japanese journal of clinical oncology, 2021, Feb-08, Volume: 51, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel

2021
The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer.
    Cancer medicine, 2021, Volume: 10, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2021
Diethylhexyl phthalate (DEHP) regulates the proliferation and chemosensitivity of esophageal squamous cell carcinoma cells via regulation of PTEN.
    Human cell, 2021, Volume: 34, Issue:4

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Diethylhexyl Phthalate; Dise

2021
NOTCH3 limits the epithelial-mesenchymal transition and predicts a favorable clinical outcome in esophageal cancer.
    Cancer medicine, 2021, Volume: 10, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch

2021
Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma.
    World journal of surgical oncology, 2021, Jul-19, Volume: 19, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous

2021
All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma.
    PloS one, 2017, Volume: 12, Issue:4

    Topics: Angiopoietin-1; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Mov

2017
A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics.
    Oncology reports, 2017, Volume: 37, Issue:5

    Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resista

2017
EGFR Expression in Patients with Esophageal Squamous Cell Carcinoma and its Association with Pathologic Response to Preoperative Chemoradiotherapy: A Study in Northeastern Iran.
    Archives of Iranian medicine, 2017, Volume: 20, Issue:4

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; ErbB Receptors; Esophageal

2017
Treatment of esophageal cancer with radiation therapy -a pan-Chinese survey of radiation oncologists.
    Oncotarget, 2017, May-23, Volume: 8, Issue:21

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan

2017
Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
    Japanese journal of clinical oncology, 2017, Aug-01, Volume: 47, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat

2017
Survival comparison between radical surgery and definitive chemoradiation in 267 esophageal squamous cell carcinomas in a single institution: A propensity-matched study.
    PloS one, 2017, Volume: 12, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C

2017
A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
    Digestive surgery, 2018, Volume: 35, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols

2018
Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
    Surgical endoscopy, 2018, Volume: 32, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Es

2018
Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma.
    Journal of cellular biochemistry, 2018, Volume: 119, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor;

2018
Long-term Clinical Results of Concurrent Chemoradiotherapy for Patients with Cervical Esophageal Squamous Cell Carcinoma.
    Anticancer research, 2017, Volume: 37, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam

2017
With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2018, Volume: 129, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Consolida

2018
Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2018, Apr-01, Volume: 31, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C

2018
Enteral nutrition and quality of life in patients undergoing chemoradiotherapy for esophageal carcinoma: a comparison of nasogastric tube, esophageal stent, and ostomy tube feeding.
    Gastrointestinal endoscopy, 2018, Volume: 88, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deglutiti

2018
Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2018, Apr-01, Volume: 31, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2018
Concurrent chemoradiotherapy alone is feasible for esophageal squamous cell carcinoma patients not suitable for surgery.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2018, Volume: 129, Issue:1

    Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Esophageal Neopl

2018
[A Case of Myocardial Metastasis of Esophageal Squamous Cell Carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat

2018
Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    The Kaohsiung journal of medical sciences, 2018, Volume: 34, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy;

2018
Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma.
    International journal of clinical oncology, 2018, Volume: 23, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Esoph

2018
Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study.
    BMC cancer, 2018, May-18, Volume: 18, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Case-Control Studie

2018
Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma.
    Journal of radiation research, 2018, Sep-01, Volume: 59, Issue:5

    Topics: Aged; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Esophageal Squamou

2018
Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
    Esophagus : official journal of the Japan Esophageal Society, 2018, Volume: 15, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esoph

2018
Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: A retrospective study.
    Journal of surgical oncology, 2018, Volume: 118, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cell Line, T

2018
The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
    BMC cancer, 2018, Aug-20, Volume: 18, Issue:1

    Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Mod

2018
Contribution of KCTD12 to esophageal squamous cell carcinoma.
    BMC cancer, 2018, Aug-29, Volume: 18, Issue:1

    Topics: Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromatin Assembly and Disas

2018
[Definitive Radiotherapy for Esophageal Squamous Cell Carcinoma after Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning of Total Body Irradiation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms;

2018
Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
    Cancer medicine, 2019, Volume: 8, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chem

2019
Tetrahydrocurcumin, Curcumin, and 5-Fluorouracil Effects on Human Esophageal Carcinoma Cells.
    Anti-cancer agents in medicinal chemistry, 2019, Volume: 19, Issue:8

    Topics: Antineoplastic Agents; Cell Proliferation; Curcumin; Dose-Response Relationship, Drug; Drug Screenin

2019
The heart's exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer: a retrospective cohort study.
    BMC cancer, 2019, Mar-04, Volume: 19, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Cardiotoxicity; Chemoradi

2019
The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.
    World journal of surgery, 2019, Volume: 43, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C

2019
Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy.
    Annals of surgical oncology, 2019, Volume: 26, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Esophageal Neoplasms;

2019
miR-145 Regulates the sensitivity of esophageal squamous cell carcinoma cells to 5-FU via targeting REV3L.
    Pathology, research and practice, 2019, Volume: 215, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding P

2019
Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 2020, Volume: 32, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis

2020
Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer.
    Medical oncology (Northwood, London, England), 2019, May-27, Volume: 36, Issue:7

    Topics: Adult; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Comb

2019
S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
    Anticancer research, 2019, Volume: 39, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combination

2019
Safety of thoracoscopic esophagectomy after induction chemotherapy for locally advanced unresectable esophageal squamous cell carcinoma.
    Asian journal of endoscopic surgery, 2020, Volume: 13, Issue:2

    Topics: Aged; Antineoplastic Agents; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Ca

2020
A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy.
    Clinical journal of gastroenterology, 2020, Volume: 13, Issue:1

    Topics: Aged; Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoxazines; Chemor

2020
Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
    Anticancer research, 2019, Volume: 39, Issue:8

    Topics: Aged; B7-H1 Antigen; Biomarkers, Tumor; CD8-Positive T-Lymphocytes; Cisplatin; Disease-Free Survival

2019
Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
    Oncology reports, 2013, Volume: 30, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2013
Significance of GSTP1 for predicting the prognosis and chemotherapeutic efficacy in esophageal squamous cell carcinoma.
    Oncology reports, 2013, Volume: 30, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemotherapy, Adj

2013
Stem cell-like side populations in esophageal cancer: a source of chemotherapy resistance and metastases.
    Stem cells and development, 2014, Jan-15, Volume: 23, Issue:2

    Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; ATP Binding Cassette Transporter, S

2014
Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
    Cancer science, 2013, Volume: 104, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell L

2013
TNF-α -857C>T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
    International journal of medical sciences, 2013, Volume: 10, Issue:12

    Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug-Related Side Effects and

2013
[A case of esophageal squamous cell carcinoma with submucosal tumor-like tumor due to direct invasion of the gastric wall].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; E

2013
A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma.
    International journal of oncology, 2014, Volume: 44, Issue:4

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; C

2014
Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
    International journal of medical sciences, 2014, Volume: 11, Issue:4

    Topics: Aged; Asian People; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Esophageal Squamous C

2014
The novel HDAC inhibitor OBP-801/YM753 enhances the effects of 5-fluorouracil with radiation on esophageal squamous carcinoma cells.
    Oncology research, 2014, Volume: 21, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Growth Processes; Cel

2014
Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer.
    International journal of clinical oncology, 2015, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem

2015
p38δ MAPK phenotype: an indicator of chemotherapeutic response in oesophageal squamous cell carcinoma.
    Anti-cancer drugs, 2015, Volume: 26, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cel

2015
[A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell

2014
Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma?
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Esophag

2014
Assessment of insulin-like growth factor 1 receptor as an oncogene in esophageal squamous cell carcinoma and its potential implication in chemotherapy.
    Oncology reports, 2014, Volume: 32, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; C

2014
Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.
    Journal of experimental & clinical cancer research : CR, 2014, Sep-01, Volume: 33

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Ce

2014
Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
    Annals of surgery, 2015, Volume: 262, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Doxorub

2015
Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma.
    BMC cancer, 2014, Sep-24, Volume: 14

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat

2014
Combination of SNX-2112 with 5-FU exhibits antagonistic effect in esophageal cancer cells.
    International journal of oncology, 2015, Volume: 46, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Drug Antagonism

2015
Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity.
    Oncology reports, 2015, Volume: 33, Issue:1

    Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; DNA Methylation; Drug Resi

2015
MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines.
    World journal of gastroenterology, 2014, Oct-28, Volume: 20, Issue:40

    Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor

2014
Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer.
    Anticancer research, 2014, Volume: 34, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2014
Local control may be the key in improving treatment outcomes of esophageal squamous cell carcinoma undergoing concurrent chemoradiation.
    Digestion, 2014, Volume: 90, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino

2014
Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma.
    Scientific reports, 2015, Jan-28, Volume: 5

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Administration

2015
Semi-radical chemoradiotherapy for 53 esophageal squamous cell carcinomas with supraclavicular lymph node metastasis in a single institutional retrospective study.
    Hepato-gastroenterology, 2014, Volume: 61, Issue:135

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; D

2014
Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells.
    European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcin

2015
Induction Chemotherapy Using FAP for Patients with Stage II/III Squamous Cell Carcinoma of the Esophagus.
    Anticancer research, 2015, Volume: 35, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined

2015
Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2016, Volume: 29, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2016
Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2015, Volume: 116, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control

2015
Salvage pharyngolaryngectomy with total esophagectomy following definitive chemoradiotherapy.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2016, Volume: 29, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C

2016
Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44(+) cancer stem cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2015, Volume: 74

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cel

2015
The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
    Surgery, 2016, Volume: 159, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2016
Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Mar-01, Volume: 22, Issue:5

    Topics: Binding, Competitive; Carcinoma, Squamous Cell; Cdc20 Proteins; Cell Line, Tumor; Cell Proliferation

2016
Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma.
    Expert opinion on therapeutic targets, 2016, Volume: 20, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2016
Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Journal of gastroenterology, 2016, Volume: 51, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C

2016
[A Case of Solitary Brain Metastasis from Stage 0 Esophageal Carcinoma after Neoadjuvant Chemotherapy Followed by Surgery].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Cell; Cisplatin

2015
Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study.
    Japanese journal of clinical oncology, 2016, Volume: 46, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2016
Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
    Hepato-gastroenterology, 2015, Volume: 62, Issue:140

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2015
Second-Line Modified FOLFOX6 Regimen in The Patients with Metastatic Esophagus Cancer.
    Hepato-gastroenterology, 2015, Volume: 62, Issue:140

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel

2015
Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, 02-01, Volume: 30, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Admin

2017
Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
    International journal of clinical oncology, 2016, Volume: 21, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C

2016
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, Feb-01, Volume: 30, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di

2017
Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2016, Volume: 32, Issue:5

    Topics: Ablation Techniques; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc

2016
Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
    Journal of surgical oncology, 2016, Volume: 113, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2016
Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom

2016
The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
    World journal of surgery, 2017, Volume: 41, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Carcinoma,

2017
Radiation field size and dose determine oncologic outcome in esophageal cancer.
    World journal of surgical oncology, 2016, Oct-13, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2016
Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols.
    BioMed research international, 2016, Volume: 2016

    Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease Pro

2016
Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway.
    Cell death & disease, 2016, 10-27, Volume: 7, Issue:10

    Topics: Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Syne

2016
Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
    Oncology, 2017, Volume: 92, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do

2017
[Preoperative Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2016
Continuous infusion of a large dose of CF (folinic acid) and 5-FU combined with CDDP in the treatment of advanced esophageal cancer.
    International journal of clinical pharmacology and therapeutics, 2017, Volume: 55, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Di

2017
THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    International journal of medical sciences, 2012, Volume: 9, Issue:9

    Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcino

2012
VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
    International journal of medical sciences, 2012, Volume: 9, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined

2012